SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Anti-CD105 [huRH105-1] Standard Size Ab04017-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa
Clone Number: huRH105-1
Alternative Name(s) of Target: endoglin; ENG
UniProt Accession Number of Target Protein: P17813
Published Application(s): in vitro, in vivo, FC
Published Species Reactivity: Rat, Human
Immunogen: The original mouse parental antibody RH105-1 was generated by intraperitoneal immunization of BALB/c VAF mice with rat CD105-expressing 300-19 cells. This antibody was synthetically engineered to mimic a binding specificity of the original RH105-1, by grafting the CDRs of the parental antibody onto human framework segments.
Specificity: The antibody binds to human and rat endoglin.
Application Notes: This antibody was used for detection of CD105 expressed on Vero cell lines by flow cytometry (Kd = 0.024 nM). The ability of the antibody to induce apoptosis on HUVEC cells was measured. Results showed that treatment with the antibody induced apoptosis of up to 47% of HUVEC cells at a concentration of 0.25 µg/mL. Further, the antibody induced a greater percentage of cells to undergo apoptosis under hypoxic conditions. The binding affinity of the antibody and the antibody conjugated to SPDB-DM4 was assayed by flow cytometry. The value of the apparent dissociation constants were calculated Kd = 1.63 nM and 2.12 nM, respectively. Treatment of HUVEC cells with huRH105-l-SMCC-DMl completely reduced viability of HUVEC cells with an EC50 of 0.12 nM in in vitro cytotoxicity experiments, while treatment of HUVEC cells with huRH105-l-SPDB-DM4 completely reduced viability with an EC50 of 0.21 nM. The antibody bound to Rat Aortic Endothelial Cells (RAOEC) by flow cytometry analysis (Kd = 0.13 nM). The ability the conjugate antibodies to inhibit cell growth of RAOEC cells was measured using an in vitro cytotoxicity assay. Treatment with huRH105-l- SMCC-DM1 completely reduced viability of RAOEC cells with an EC50of 0.48 nM for huRH105-l-SMCC-DMl and 1.1 nM for huRH105-l-SPDB-DM4. Analysis of in vivo efficacy of huRH105-l-SMCC-DMl in combination with bevacizumab in A2780 and HCT116 rat xenograft models showed improved efficacy compared to the control experiment. Analysis of in vivo efficacy of

huRH105-l-SMCC-DMl alone in an U87MG rat xenograft model showed improved efficacy compared to the control experiment (WO2012149412A2).
Antibody First Published in: PMID:
Note on publication:

Product Form

Size: 100 µg Purified antibody.
Purification: Protein A affinity purified
Supplied In: PBS with 0.02% Proclin 300.
Storage Recommendation: Store at 4^{o}C for up to 3 months. For longer storage, aliquot and store at -20^{o}C.
Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.